New study tests drug to shrink kidney tumors in rare genetic disorder
NCT ID NCT05252585
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 34 times
Summary
This study looks at the safety and effectiveness of the drug everolimus in Taiwanese adults with tuberous sclerosis complex who have kidney tumors called angiomyolipomas. Four participants will take the medication to see if it reduces tumor size and to monitor any side effects. The goal is to control the disease rather than cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL ANGIOMYOLIPOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Taichung, Taiwan ROC, 40201, Taiwan
-
Novartis Investigative Site
Taoyuan, Taiwan ROC, 33305, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
Conditions
Explore the condition pages connected to this study.